Skip to main content

Becton Dickinson Q3 FY2026 results

  • BDX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$218.03+1.08%Close 13 Nov 2026 · Market value $59.20B

Becton Dickinson reported revenue of $4.98 billion, down 9.5% from a year earlier, net income of $377 million and diluted earnings per share of $1.37 against $2.00 for the third quarter of fiscal 2026 (the three months to 30 Jun 2026).

From its quarterly report, filed 6 Aug 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Jun 2026, against the three months to 30 Jun 2025. Amounts in USD.

Becton Dickinson Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$4.98B$5.51B−9.5%
Gross profit$2.31B$2.63B−12.1%
Gross margin46.5%47.8%−1.4 pts
Operating income$663.0M$882.0M−24.8%
Operating margin13.3%16.0%−2.7 pts
Net income$377.0M$574.0M−34.3%
Diluted EPS$1.37$2.00−31.5%
Operating cash flow$651.0M$1.22B−46.6%
Capital expenditure$143.0M$164.0M−12.8%
Free cash flow$508.0M$1.05B−51.8%

Operating KPIs for the quarter

Becton Dickinson operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Medical Essentials revenue$1.7Bup 4.6%
Interventional revenue$1.4Bup 6.5%
Connected Care revenue$1.2Bup 5.0%
BioPharma Systems revenue$670.0Mup 6.5%
United States revenue$3.1Bup 6.9%
International revenue$1.9Bup 3.1%

Earlier quarters

Becton Dickinson results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Jun 2026$4.98B−9.5%$1.37
Q2 FY202631 Mar 2026$4.71B−10.6%−$1.11
Q1 FY202631 Dec 2025$5.25B+1.6%$1.34
Q4 FY202530 Sep 2025$5.89B+8.4%$1.71
Q3 FY202530 Jun 2025$5.51B+10.4%$2.00
Q2 FY202531 Mar 2025$5.27B+4.5%$1.07
Q1 FY202531 Dec 2024$5.17B+9.8%$1.04
Q4 FY202430 Sep 2024$5.44B+6.9%$1.37

More on Becton Dickinson: financial statements · revenue · earnings per share

BDX's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.